ATH 13.7% 4.4¢ alterity therapeutics limited


  1. 1,336 Posts.
    lightbulb Created with Sketch. 22
    The truth is, the falling SP currently is reflective of PBT2 being the last bastion of hope for Prana - and it being a dying light at that - when its moving into phase 3 in HD, with AD likely to follow and its just one of many compounds in the pipeline with  human trials commencing this year on PBT434..  This next compound will not only target PD but many diseases associated with movement disorders, with a possible end game being both PBT2 and PBT434 being used in conjunction to treat both cognition and movement disabilities associated with neuro degenerative conditions.

    Kad posted this elsewhere on YMB a couple of days ago..
    The Parkinson's drug
    Very impressive animal testing this time by the independent Leeds University team. Due in clinic 2015.
    From the report:
    "While this financial year began with much attention focused on trial results for PBT2, one of our other development products also received an important boost when Parkinson’s UK awarded £150,000 to the University of Leeds to study the mechanism of PBT434. In three different animal models of Parkinson’s Disease, PBT434 has proven effective in preventing neuronal loss and preserving motor function, and we continue to develop the drug as one compound in a library of more than 1000 Metal Protein Attenuating Compounds (MPACs). " and
    "Prana’s lead development compound for movement disorders, PBT434, has been shown to prevent the aggregation of a key protein, alpha synuclein, implicated in the pathology of Parkinson’s Disease (PD) and other movement disorders such as Multiple System Atrophy. These findings together with the demonstration that PBT434 can preserve the neurons that perish in PD, were presented at the 17th Movement Disorders Congress of Parkinson’s Disease and Movement Disorders in Sydney in June 2013. Research into the potential disease modifying mechanisms of the drug has been assisted by the award of £150,000 grant from Parkinson’s UK to The University of Leeds to study PBT434 in collaboration with Melbourne’s Florey Institute of Neuroscience and Mental Health. Development of the drug has progressed into longer term toxicology studies and GMP manufacture of the drug to enable first in man studies in 2015."
    At this price strong buy does not go far enough
    Last edited by m123456: 16/02/15
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Mkt cap ! $37.87M
Open High Low Value Volume
4.6¢ 4.6¢ 4.4¢ $10.3K 225K

Buyers (Bids)

No. Vol. Price($)
1 15000 4.4¢

Sellers (Offers)

Price($) Vol. No.
5.1¢ 120020 2
View Market Depth
Last update - 15.58pm 19/04/2019 (20 minute delay) ?
ATH (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.